|
Press Releases |
|
|
|
Friday, January 10, 2020 |
|
SinoMab Granted the "Most Popular Newly Listed Company" Award |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the Group has won the title of the "Most Popular Newly Listed Company" at the 4th Hong Kong Golden Stocks Awards held in Shenzhen. more info >> |
|
Wednesday, November 20, 2019 |
|
类风湿关节炎治疗市场蓝海潜力巨大 中国抗体公布在研药物SM03类风湿关节炎III期临床试验最新进展 |
中国抗体制药有限公司(「中国抗体」或「公司」,连同其附属公司,统称「集团」;股份代号:3681.HK),专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司,欣然宣布其旗舰在研药物SM03类风湿关节炎III期临床试验最新进展。 more info >> |
|
類風濕關節炎治療市場藍海潛力巨大 中國抗體公佈在研藥物SM03類風濕關節炎III期臨床試驗最新進展 |
中國抗體製藥有限公司(「中國抗體」或「公司」,連同其附屬公司,統稱「集團」;股份代號:3681.HK),專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司,欣然宣佈其旗艦在研藥物SM03類風濕關節炎III期臨床試驗最新進展。 more info >> |
|
Great Potential in RA Therapeutic Market, Sinomab Announces Latest Progress of its Drug Candidate SM03 Phase III Clinical Trial for the Treatment RA |
SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce its latest progress of SM03 phase III clinical trial for the treatment rheumatoid arthritis. more info >> |
|
Monday, November 11, 2019 |
|
中国抗体(3681.HK):商业化进程未来可期 |
2018年港交所设立新规,允许未盈利公司在香港主板上市,由此揭开了内地生物科技公司赴港上市热潮的序幕。 more info >> |
|
中國抗體(3681.HK):商業化進程未來可期 |
2018年港交所設立新規,允許未盈利公司在香港主板上市,由此揭開了內地生物科技公司赴港上市熱潮的序幕。 more info >> |
|
Wednesday, October 30, 2019 |
|
中国抗体制药宣布于港交所主板上市计划 |
中国抗体制药有限公司(「中国抗体制药」或「公司」连同其附属公司,统称「集团」;股份代号:3681.HK),专门研究、发展、制造及商业化免疫性疾病疗法且主要研制以单克隆抗体为基础的生物药的香港生物制药公司,今天宣布于香港联合交易所有限公司(「联交所」)主板上市计划。 more info >> |
|
中國抗體製藥宣佈於港交所主板上市計劃 |
中國抗體製藥有限公司(「中國抗體製藥」或「公司」連同其附屬公司,統稱「集團」;股份代號:3681.HK),專門研究、發展、製造及商業化免疫性疾病療法且主要研製以單克隆抗體為基礎的生物藥的香港生物製藥公司,今天宣佈於香港聯合交易所有限公司(「聯交所」)主板上市計劃。 more info >> |
|
SinoMab BioScience Announces Proposed Listing on the Main Board of SEHK |
SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Domino's Pizza Inc. Is Being Investigated by Kaplan Fox & Kilsheimer LLP for Potential Securities Law Violations
Jul 26, 2024 23:30 HKT/SGT
|
|
|
CORRECTION FROM SOURCE: Doubleview Reports Maiden Mineral Resource Estimate
Jul 26, 2024 21:00 HKT/SGT
|
|
|
CITIC Resources Announces its 2024 Interim Results
Jul 26, 2024 20:43 HKT/SGT
|
|
|
中信資源公布2024年度中期業績 收入大幅增長93.1%至約39.4億港元
Jul 26, 2024 20:29 HKT/SGT
|
|
|
OmniGuide Holdings Announces Successful Completion of Patient Study for Revolutionary iSTONE(TM) Laser-Guided Lithotripsy Technology
Jul 26, 2024 20:05 HKT/SGT
|
|
|
VCI Global Enters into AI Computing Alliance (AICA) Led by Enlight Corporation and Supermicro
Jul 26, 2024 20:00 HKT/SGT
|
|
|
中信资源公布2024年度中期业绩 收入大幅增长93.1%至约39.4亿港元
Jul 26, 2024 19:57 HKT/SGT
|
|
|
華邦科技集團成員及策略夥伴攬獲「專業金融機構服務大獎2024」兩項殊榮 [更新版]
Jul 26, 2024 17:42 HKT/SGT
|
|
|
华邦科技集团成员及策略伙伴揽获“专业金融机构服务大奖2024”两项殊荣[更新版]
Jul 26, 2024 17:18 HKT/SGT
|
|
|
DOCOMO and NTT Com Jointly Demonstrate Practicality of DOCOMO's New Multi-platform Cloud-rendering Technology
Jul 26, 2024 17:05 JST
|
|
|
Kucingko Berhad Debuts on ACE Market with Clawsome Opening Price of RM0.805
Jul 26, 2024 16:00: JST
|
|
|
Kucingko Berhad Debuts on ACE Market with Clawsome Opening Price of RM0.805
Jul 26, 2024 15:00 HKT/SGT
|
|
|
華邦科技旗下公司攬獲「專業金融機構服務大獎2024」兩項殊榮
Jul 26, 2024 13:26 HKT/SGT
|
|
|
华邦科技旗下公司揽获“专业金融机构服务大奖2024”两项殊荣
Jul 26, 2024 13:15 HKT/SGT
|
|
|
British Veterinary Association Ends Opposition to Vegan Diets for Dogs
Jul 26, 2024 02:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|